References:
[1] Concha J, Tarazi M, Kushner CJ, Gaffney RG, Werth VP. The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria. Br J Dermatol 2019; 180: 1001-1008.
[2] Ortiz-Santamaria V, Babot A, Ferrer C. Anti-MDA5-positive dermatomyositis: an emerging entity with a variable clinical presentation. SCAND J RHEUMATOL 2017; 46: 509-511.
[3] Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010; 146: 26-30.
[4] Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S et al.. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. CHEST 2009; 136: 1341-1347.
[5] Motegi SI, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M et al.. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. EUR J DERMATOL 2019; 29: 511-517.
[6] Lee YJ, Kim DJ, Kim JS, Lee JH, Lee CT, Jheon S et al.. Experience and results with VV-ECMO for severe acute respiratory failure: weaning versus nonweaning. ASAIO J 2015; 61: 184-189.
[7] Abrams DC, Prager K, Blinderman CD, Burkart KM, Brodie D. Ethical dilemmas encountered with the use of extracorporeal membrane oxygenation in adults. CHEST 2014; 145: 876-882.
[8] Chen S, Hu J, Xu L, Brandon D, Yu J, Zhang J. Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review. MOL NEUROBIOL 2016; 53: 6897-6909.
[9] Dhar R. Neurologic Complications of Transplantation. NEUROCRIT CARE 2018; 28: 4-11.
[10] Li J, Liu Y, Li Y, Li F, Wang K, Pan W et al.. Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: A systematic meta-analysis. J DERMATOL 2018; 45: 46-52.
[11] Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y et al.. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 2012; 51: 1563-1570.
[12] Gan YZ, Zhang LH, Ma L, Sun F, Li YH, An Y et al.. Risk factors of interstitial lung diseases in clinically amyopathic dermatomyositis. Chin Med J (Engl) 2020: 644-649.
[13] Bakhshaee M, Jokar MH, Mirfeizi Z, Atabati E, Tarighat S. Subcutaneous Emphysema, Pneumomediastinum and Pneumothorax in a Patient with Dermatomyositis. Iran J Otorhinolaryngol 2017; 29: 113-116.
[14] Said SA, Okamoto T, Sakanoue I, Unai S, Budev M, Akindipe O et al.. Lung Transplant for Patient with Idiopathic Pneumonia Syndrome. ANN THORAC SURG 2020.